Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere
NANJING, China, March 22, 2013
NANJING, China, March 22, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group
("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company
specializing in the development, manufacturing, and marketing of branded and
proprietary pharmaceuticals in China, today announced that the Chinese SFDA
has issued its approval for GMP certification of the influenza vaccine
production facility at Jiangsu Simcere Vaxtec Bio-Pharmaceutical Co., Ltd
("Simcere Vaxtec"), a subsidiary in which the Company holds a 52.5% equity
interest.Simcere Vaxtec plans to resume production of its influenza vaccine.
Separately, the Company also announced the resignation of Mr. Hong Zhao, an
executive vice president of the Company. Mr. Zhao resigned for personal
reasons. His resignation has been accepted by the Company and will take into
effect on April 1, 2013.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a
leading pharmaceutical company specializing in the development, manufacturing,
and marketing of branded and proprietary pharmaceuticals in China. Simcere
concentrates its research and development efforts on the treatment of diseases
with high incidence and/or mortality rates and for which there is a clear
demand for more effective pharmacotherapy such as cancer, strokes,
cardiovascular disease, infectious diseases and pain. For more information
about Simcere Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contacts:
Jie Liu D'Elia In the United States:
Vice President Cindy Zheng
Simcere Pharmaceutical Group Brunswick Group LLC
Tel: 86-25-8556-6666*8857 Tel: 1-212-333-3810
SOURCE Simcere Pharmaceutical Group
Press spacebar to pause and continue. Press esc to stop.